Quetiapine: A review of its safety in the management of schizophrenia

Drug Safety

Volumn 23, Issue 4, 2000, Pages 295-307

  Dev, V ^a   Raniwalla, J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; KETOCONAZOLE; PHENYTOIN; PIMOZIDE; QUETIAPINE; RIFAMPICIN; RISPERIDONE; SEROTONIN 2A RECEPTOR; THIORIDAZINE;

AKATHISIA; CLINICAL TRIAL; DOSE CALCULATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERANCE; DYSKINESIA; DYSTONIA; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 0033782694     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200023040-00003     Document Type: Review

References (56)

1. Seroquel: Biochemical profile of a potential atypical antipsychotic
2. Seroquel (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic
3. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
4. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo
5. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
6. A multicenter, double-blind, randomised comparison of dose and dose regimen of 'Seroquel' in the treatment of patients with schizophrenia
7. A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of, and a demonstrated, partial response to conventional antipsychotic treatment
8. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia
9. Quetiapine and risperidone in outpatients with psychotic disorders: Results of the QUEST trial
10. Why do schizophrenic patients refuse to take their drugs?
11. Antipsychotic tolerability: The attitudes and perceptions of medical professionals, patients and caregivers towards the side effects of antipsychotic therapy
12. Conditions predisposing to suicide: A review
13. Schizophrenics kill themselves too: A review of risk factors for suicide
14. Patients' satisfaction with, and acceptability of, atypical antipsychotics
15. Patient satisfaction and acceptability of long-term treatment with quetiapine
16. Preclinical profile of 'Seroquel' (quetiapine): An atypical antipsychotic with clozapine-like pharmacology
17. Antipsychotic-induced side effects related to receptor affinity
18. Adverse events of antipsychotic drugs
19. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients
20. Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses
21. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug
22. Activity of 'Seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine
23. Prospective study of tardive dyskinesia
24. Rarity of persistent tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly
25. The neuroleptic malignant syndrome: Agent and last interaction
26. Neuroleptic malignant syndrome. Diagnosis, epidemiology and treatment
27. Quetiapine. A review of its use in schizophrenia
28. Falls and psychotropic drug consumption in long-term careresidents: Is there an obvious association?
29. The association between medications and falls in Australian nursing-home residents
30. Schizophrenia: The epidemiological horizon
31. The association between antipsychotic drugs and sudden death
32. Seroquel (quetiapine fumarate): A new atypical antipsychotic
33. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety
34. Side effects of new antipsychotic agents
35. Risperidone
36. Medication non-compliance in schizophrenia: Codification and update
37. A prospective, multicenter study of patients' refusal of antipsychotic medication
38. Quetiapine and prolactin: Low incidence of side effects referable to hyperprolactinemia is consistent with quetiapine's minimal effects on plasma prolactin
39. Low incidence of reproductive/hormonal side effects with 'Seroquel' (quetiapine) is supported by its lack of elevation of plasma prolactin concentrations
40. Ocular abnormalities in chronic schizophrenia: Clinical implications
41. Limitations of epidemiology on understanding pathogenesis of cataracts
42. Schizophrenia, psychotropic medication, and cataract
43. Adverse effects of the atypical antipsychotics
44. Weight changes in patients treated with Seroquel (quetiapine)
45. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control
46. Loss of consciousness from acute quetiapine overdosage
47. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment
48. The effect of phenytoin and cimetidine on the pharmacokinetics of 'Seroquel'
49. Pharmacokinetics and safety of lithium co-administered with 'Seroquel' (quetiapine)
50. Effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics of quetiapine
51. Treatment of schizophrenia and delusional disorder in the elderly
52. Clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorders treated with Seroquel (quetiapine)
53. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate in adolescents with selected psychotic disorders
54. The long-term efficacy and safety of 'Seroquel' (quetiapine)